HUTCHMED announces completion of patient enrollment for the SAFFRON Phase III study, testing ORPATHYS® and TAGRISSO® for EGFR-mutated, MET-overexpressed NSCLC. Results expected in early 2026, supporting potential global regulatory filings if favorable. SAFFRON is a global study with 338 patients from 29 countries, evaluating progression-free survival and other endpoints. ORPATHYS® is an oral MET TKI, while TAGRISSO® is an EGFR TKI. Both drugs have shown promise in treating NSCLC. The combination aims to offer a chemotherapy-free option for patients after progression on EGFR TKI treatment.

MET aberrations play a role in resistance to EGFR TKIs in NSCLC. ORPATHYS® is a selective MET inhibitor with clinical activity in advanced solid tumors. TAGRISSO® is a third-generation EGFR TKI with proven efficacy in NSCLC. The combination of ORPATHYS® and TAGRISSO® targets resistant mechanisms in EGFR-mutated NSCLC. Strong data from previous studies support this combination’s effectiveness, leading to ongoing Phase III trials like SAFFRON and SANOVO. The results will help guide potential global registration filings for the combination therapy.

HUTCHMED is a biopharmaceutical company focused on developing targeted therapies for cancer and immunological diseases. ORPATHYS® and TAGRISSO® are part of their innovative portfolio, with ongoing trials exploring their efficacy in treating EGFR-mutated NSCLC. The company is committed to bringing new treatment options from discovery to patients worldwide. The combination of ORPATHYS® and TAGRISSO® offers hope for patients with resistant NSCLC, addressing an unmet need in the treatment landscape.

Read more at GlobeNewswire: HUTCHMED Announces Enrollment Completed of SAFFRON Global